Clinical trials: Antibody
Acute Myeloid Leukemia Refractory
Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX]
The aim of this study is to investigate the safety and the clinical activities of NP137 when combined with Azacitidine and Venetoclax in patients with refractory acute myeloid leukemia after 2 cycles of Azacitidine and Venetoclax.
- Trial name
- AML-NET (NCT06150040)
- Testing
- NP137, Azacitidine Injection, Venetoclax
- Where
- France
- Volunteers
- 1 people
- Sponsor
- Centre Leon Berard
Extranodal NK/T-cell Lymphoma, Nasal Type
Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell Lymphoma
For patients with NK/T-cell lymphoma, plasma EBV-DNA has been found to be a prognostic factor, and those with positive plasma EBV-DNA at the end of treatments are more likely to suffer from disease relapse.
- Trial name
- NCT04338282
- Testing
- toripalimab
- Volunteers
- 20 people
- Sponsor
- Beijing Tongren Hospital
Progressive Multiple Sclerosis
Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis
This is a is a small scale open phase two interventional study to assess long-term stabilising effects of on neurological symptoms by regular intrathecal administered monoclonal antibodies in progressive multiple sclerosis.
- Trial name
- ITT-PMS (NCT01719159)
- Testing
- Rituximab
- Where
- 2 sites in Sweden
- Volunteers
- 23 people
- Sponsor
- Anders Svenningsson
Leukemia, Lymphocytic
Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia
Background: Chronic lymphocytic leukemia (CLL) is a blood cancer. Recombinant human interleukin 15 (IL-15) is a manmade protein. Obinutuzumab is a protein made to deactivate cancer cells.
- Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell
- Trial name
- NCT03759184
- Testing
- rhIL-15, Obinutuzumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Healthy
An Open Study of the Safety and Pharmacokinetics of a Medicinal Product for Emergency Prevention of Ebola
This Phase I clinical trial was developed to study drug safety, tolerability, and pharmacokinetics of the medicine for Ebola fever emergency prevention based on monoclonal recombinant antibodies in single use in healthy…
- Trial name
- 03-AT-2017 (NCT03428347)
- Testing
- GamEMab
- Where
- Russia
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Moderate to Severe Plaque Psoriasis
Effectiveness of Adalimumab in Moderate to Severe Plaque Psoriasis Patients With Distinct Co-morbidities
This multicenter, post marketing observational study (PMOS) was designed to evaluate the effectiveness of adalimumab over a period of 9 months as determined by the Psoriasis Area and Severity Index (PASI) in participants with…
- Trial name
- EPIC (NCT01401452)
- Volunteers
- 246 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Melanoma
A Study of HX008 for the Treatment of Patients With Malignant Melanoma
HX008 is a humanized monoclonal antibody targeting PD-1 on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
- Trial name
- NCT04749485
- Testing
- HX008
- Where
- 11 sites in China
- Volunteers
- 119 people
- Sponsor
- Taizhou Hanzhong biomedical co. LTD
Meningococcal Disease
Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine
The primary purpose of this study is to evaluate the persistence of bactericidal antibodies in children of approximately 22 to 45 months of age previously enrolled in the V59P22 study (NCT00667602) who received Novartis MenACWY…
- Trial name
- NCT01345721
- Testing
- MenACWY-CRM
- Where
- 11 sites in Germany
- Volunteers
- 205 people
- Sponsor
- Novartis Vaccines
Colon Cancer Adenocarcinoma
A Phase Ib/II Study to Evaluate HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Metastatic Colorectal Cancer
This study is a phase Ib/II study to evaluate the efficacy, safety and tolerance of HLX43 combined with HLX07 or Serplulimab in patients with advanced or metastatic colorectal cancer failed or intolerance to standard first-line…
- Trial name
- NCT07358585
- Testing
- HLX43 dose 1 + HLX07, HLX43 dose 2 + HLX07, HLX43 dose 3 + Serplulimab
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Shanghai Henlius Biotech
Aplastic Anemia
CsA+ATG+AVA vs. CsA+AVA for the Treatment of Newly-diagnosed SAA in the Elderly
This is a multicenter, prospective, randonmized study. Our previous retrospective study showed that for SAA patients who were intolerant to ATG, CsA+ eltrombopag (EPAG) had similar efficacy to CsA+ATG+EPAG.
- Trial name
- NCT05996393
- Testing
- Ciclosporin, Avatrombopag, Anti-Human Thymocyte Immunoglobulin, Rabbit
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Peking Union Medical College Hospital
Brain Cancer, Brain Neoplasm
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
Glioblastoma (GBM) and gliosarcoma (GS) are the most common and aggressive forms of malignant brain tumor in adults and can be resistant to conventional therapies.
- Conditions
- Brain Cancer, Brain Neoplasm, Glioma, Glioblastoma
- Trial name
- CAPTIVE (NCT02798406)
- Testing
- DNX-2401, pembrolizumab
- Where
- 15 sites in United States, Canada
- Volunteers
- 49 people
- Sponsor
- DNAtrix, Inc.
Arthritis, Rheumatoid
A Placebo-Controlled, Double-Blinded, Randomized Trial of Remicade in Korean Patients With Rheumatoid Arthritis Despite Methotrexate (Study P04280)(COMPLETED)
Prior to the first infusion, patients will be randomized into one of two groups (placebo or infliximab). All patients will continue to receive the same does of methotrexate (MTX) during the study as received prior to the study.
- Trial name
- NCT00202852
- Testing
- MTX, Infliximab
- Volunteers
- 143 people
- Sponsor
- Merck Sharp & Dohme LLC
Spondylitis, Ankylosing, Arthritis, Psoriatic
A Study of Golimumab in the Treatment of Indian Participants With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis
The purpose of this study is to assess the safety of subcutaneous (SC) golimumab in participants with active Ankylosing Spondylitis (AS) or Psoriatic Arthritis (PsA) over 24 weeks.
- Trial name
- NCT03733925
- Testing
- Golimumab
- Where
- 9 sites in India
- Volunteers
- 100 people
- Sponsor
- Johnson & Johnson Private Limited
Churg-Strauss Syndrome
Immuno-ablation With Chemoimmunoradiation and Autologous Stem Cell Transplant for Churg-Strauss Syndrome
Churg-Strauss syndrome is a rare autoimmune inflammatory disease affecting medium- and small-sized blood vessels, causing asthma, abnormalities of the blood, lung diseases, and neuropathy.
- Trial name
- NCT02728271
- Testing
- HPC cell infusion
- Volunteers
- 1 people
- Sponsor
- Mounzer Agha
SARS-CoV2, COVID-19
Are SARS-CoV-2 Specific Antibodies a Correlate for Protection?
The objectives of this study are (1) to determine the ex vivo neutralizing capacity and the longevity of SARS-CoV-2-specific Ab responses and (2) to measure the memory B-cell responses in a cohort of health care workers (HCW)…
- Trial name
- ImmCoV (NCT04469634)
- Testing
- Assessing antibody responses, neutralizing capacity and memory B-cell function
- Where
- 2 sites in Belgium
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Adult T-cell Leukemia-Lymphoma
KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
The purpose of this study is to estimate the overall response rate of subjects with relapsed or refractory Adult T-cell Leukemia-Lymphoma (ATL).
- Trial name
- NCT01626664
- Testing
- KW-0761, Pralatrexate, gemcitabine plus oxaliplatin
- Where
- 20 sites in United States, Belgium and 4 more
- Volunteers
- 71 people
- Sponsor
- Kyowa Kirin, Inc.
Chronic Hepatitis B
Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects
This is the first in human study of 162, and the primary objective is to evaluate the safety and tolerability of 162 with a single ascending dose in healthy adult subjects.
- Trial name
- NCT05310487
- Testing
- 162
- Where
- Australia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Yangshengtang Co., Ltd
Non Small Cell Lung Cancer
A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E Mutation
An open-label, multicenter phase Ib/II clinical study to evaluate safety, tolerability, pharmacokinetics, and efficacy of HLX208 (BRAF V600E Inhibitor) combined with HLX10 （anti-PD-1 monoclonal antibody）in advanced NSCLC patients…
- Trial name
- NCT05641493
- Testing
- HLX208+HLX10
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Shanghai Henlius Biotech
Diarrhea Due to Clostridium Difficile
Host Immune Response to Clostridium Difficile Infection (ICD)
Clostridium difficile is responsible for up to 25% of reported antibiotic associated diarrhea cases and virtually all cases of pseudomembranous colitis (PMC). The clinical spectrum of C.
- Trial name
- ICD (NCT02440438)
- Testing
- Blood sampling
- Where
- France
- Volunteers
- 56 people
- Sponsor
- Hospices Civils de Lyon
HIV Antibodies
Phase I, Open-Label, Dose-Escalation Study of a Human Monoclonal Antibody, VRC-HIVMAB091-00-AB (N6LS), Administered Intravenously or Subcutaneously With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)
Background: The experimental product in this study, N6LS, is a human monoclonal antibody. Antibodies are one way that the human body fights infection. Monoclonal means that all the antibodies in the product are the same.
- Trial name
- VRC 609 (NCT03538626)
- Testing
- VRC-HIVMAB091-00-AB, rHuPH20
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.